Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc Reaffirms FY 2013 Guidance; Issues Q3 2013 Revenue Guidance Below Analysts' Estimates


Monday, 5 Aug 2013 04:01pm EDT 

Emergent BioSolutions Inc reaffirmed its forecast for fiscal 2013 total revenues of $290 million to $310 million, split between product revenues of $235 million to $245 million and contracts and grants revenue of $55 million to $65 million. The Company also reaffirmed its forecast for fiscal 2013 net income of $20 million to $30 million. For the third quarter of 2013, the Company forecasts total revenues of $70 to $80 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $299 million and net income of $27 million for fiscal 2013; and revenue of $81 million for the third quarter of 2013. 

Related Company News

Company Quote

27.05
0.07 +0.26%
19 Dec 2014